BioSpace News Archive

Mevion Medical Systems announced that it has been selected to install a MEVION S250i Proton Therapy System with HYPERSCAN Pencil Beam Scanning at the Levine Cancer Institute at Atrium Health in North Carolina.

Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, today announced that the first patient has been successfully enrolled into a Phase 1 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) in China.

Total revenue of $108.1 million in 2020, up 26 percent year-over-year Software revenue of $92.5 million in 2020, up 39 percent year-over-year Strong financial position enables continued investment in advancing the science underlying Schrödinger’s computational platform Internal pipeline progressing, with plans to submit investigational new drug applications in 2022 Conference call today, Thursday, March 4, at 8:30 a.m. ET

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced the publication of a case report using the company’s CaspaCIDe (inducible caspase-9, or iC9) safety switch.

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) (the “Company” or “Dicerna”), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, announced today that Roche has initiated RG6346 in a Roche-sponsored Phase 2 combination trial for the treatment of chronic hepatitis B virus (HBV) infection.

Creative Medical Technology Holdings announced today a publication in the pre-print server SSRN describing data from its first 15 patients treated in a clinical trial evaluation perispinal injection of bone marrow cells in patients with disc degenerative disease.

Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that that it plans to host a conference call on Thursday, March 11, 2020, at 8:30 a.m.

Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announces the appointment of industry stalwart Alistair Longmuir as an advisor for their global product manufacture strategy.

Replimune Group, Inc. (Nasdaq: REPL), a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic™ platform, today announced that members from the Replimune management team will present and host one-on-one meetings at the following three virtual investor conferences. H.C. Wainwright Global Life Sciences Conference Date: March 9-10, 2021 Pre-Recorded Formal Presentation will be made live: Tuesday, March 9, 2021

Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing masked, protease-activated immune-oncology therapeutics to bring the promise of these potent therapies to patients with solid tumor cancers, today announced that it has raised $117 million Series B financing.